New England Peptide Announces License Agreement
New England Peptide acquires next generation exosome and microvesicle affinity technology for potential detection of cancer and other diseases.
Gardner, MA (PRWEB) March 07, 2013
New England Peptide, Inc. (NEP) today announced that it has entered into a licensing agreement with the Atlantic Cancer Research Institute (ACRI). Under the terms of the agreement NEP has acquired the worldwide exclusive rights for Vn96 and a portfolio of other peptide compounds to be used for the research grade enrichment of microparticles, microvesicles, and exosomes. NEP will be releasing a research grade affinity enrichment kit next quarter. ACRI and NEP, co-inventors of Vn96, are actively seeking collaborators for the clinical use of Vn96.
“We believe that Vn96, coupled with advancing genomic and proteomic biomarker research, will lead to a promising array of diagnostic applications for disease detection,” commented Sam Massoni, President and CEO of NEP. “Our goal is for it to be the first step of a simple blood test that could provide early detection of hundreds of specific diseases“¦each with its own protein or nucleic acid profile, all performed as part of a routine physical in the doctor´s office.”
According to Dr. Rodney Ouellette, President and Scientific Director of ACRI, “You can think of microvesicles as a facsimile of a diseased cell that contain the same altered genes and proteins that you would find in sample obtained from a surgical biopsy. Microvesicles circulate in blood or urine, so important diagnostic or prognostic information can be collected simply and used for either research or clinical analysis.”
“Previous exosome capture methods such as ultracentrifugation could leave a lot to be desired in regards to time, effort and accessibility of equipment,” adds co-inventor Scott Lewis, Director, Antibody Division at NEP. “Vn96 specifically attaches to circulating exosomes, which allows for easy, simple and quick enrichment, and ultimately faster research.”
This agreement is further evidence of New England Peptide´s commitment to collaborate with its customers to develop and manufacture important research tools. NEP plans to manufacture the research grade kit in its current Massachusetts facility.
About Atlantic Cancer Research Institute (ACRI)
The Atlantic Cancer Research Institute (ACRI) is a non-profit organization founded in 1998 and housed at the Dr. Georges-L. Dumont University Hospital Centre in Moncton, New Brunswick. Thanks to its unique expertise, the ACRI has become a true centre of excellence in cancer research. Scientists are working with partners in Canada and around the world to discover the genetic origins of cancer and pursuing three main areas of development: early screening; enhanced diagnosis, and targeted treatment. More information can be found at http://www.atlanticcancer.ca or on Facebook Atlantic Cancer Research.
About New England Peptide (NEP)
New England Peptide, founded in 1998, designs and manufactures peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. Headquartered in the Boston metro area in Gardner, Mass., the company´s chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications. More information on NEP can be found at http://www.newenglandpeptide.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/3/prweb10499181.htm